Thiopurine treatment in inflammatory bowel disease

被引：3
|
作者：
Gardiner, Sharon J. [1 ]
Begg, Evan J.
Sau, Ashis
Marinaki, Anthony
Gearry, Richard B.
Barclay, Murray L.
机构：
[1] Christchurch Sch Med, Dept Med, Christchurch, New Zealand
[2] Univ Hosp Lewisham, Dept Obstet & Gynaecol, London, England
[3] Guys Hosp, Dept Clin Pathol, Purine Res Lab, London, England
[4] Christchurch Hosp, Dept Gastroenterol, Christchurch, New Zealand
来源：
CLINICAL PHARMACOKINETICS | 2007年 / 46卷 / 09期
关键词：
D O I：
10.2165/00003088-200746090-00007
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：803 / 804
页数：2
相关论文
共 50 条
  • [21] Thiopurine metabolites and the role of thiopurine methyltransferase activity in inflammatory bowel disease
    Qasim, A
    Buckley, M
    O' Morain, CA
    [J]. GUT, 2002, 51 (01) : 141 - 141
  • [22] Review article: malignancy on thiopurine treatment with special reference to inflammatory bowel disease
    Smith, M. A.
    Irving, P. M.
    Marinaki, A. M.
    Sanderson, J. D.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2010, 32 (02) : 119 - 130
  • [23] Sperm DNA Integrity is Unaffected by Thiopurine Treatment in Men With Inflammatory Bowel Disease
    Grosen, Anne
    Nersting, Jacob
    Bungum, Mona
    Christensen, Lisbet Ambrosius
    Schmiegelow, Kjeld
    Spano, Marcello
    Julsgaard, Mette
    Cordelli, Eugenia
    Leter, Giorgio
    Larsen, Peter Braad
    Hvas, Christian Lodberg
    Kelsen, Jens
    [J]. JOURNAL OF CROHNS & COLITIS, 2019, 13 (01): : 3 - 11
  • [24] Metabolite measurement for thiopurine therapy in inflammatory bowel disease
    Sanchez Rodriguez, E.
    Rios Leon, R.
    Flores de Miguel, A.
    Guerrero Garcia, A.
    Albillos Martinez, A.
    Lopez Sanroman, A.
    [J]. JOURNAL OF CROHNS & COLITIS, 2018, 12 : S314 - S314
  • [25] The role of thiopurine metabolite monitoring in inflammatory bowel disease
    Beswick, Lauren
    Friedman, Antony B.
    Sparrow, Miles P.
    [J]. EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2014, 8 (04) : 383 - 392
  • [26] Thiopurine metabolite monitoring in paediatric inflammatory bowel disease
    Ooi, C. Y.
    Bohane, T. D.
    Lee, D.
    Naidoo, D.
    Day, A. S.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2007, 25 (08) : 941 - 947
  • [27] Towards optimal thiopurine therapy for inflammatory bowel disease
    van Liere, Elsa L. S. A.
    de Boer, Nanne K. H.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2024, 59 (06) : 792 - 793
  • [28] Cytotoxicity of Thiopurine Drugs in Patients with Inflammatory Bowel Disease
    Zakerska-Banaszak, Oliwia
    Lykowska-Szuber, Liliana
    Walczak, Michal
    Zuraszek, Joanna
    Zielinska, Aleksandra
    Skrzypczak-Zielinska, Marzena
    [J]. TOXICS, 2022, 10 (04)
  • [29] Thiopurine adverse events in patients with inflammatory bowel disease in the UK: inflammatory bowel disease BioResource cohort
    Hong, Y. Y.
    Withanachchi, D. A.
    Aslam, S. P.
    Khalid, Y.
    Shawky, R.
    Parkes, M.
    [J]. JOURNAL OF CROHNS & COLITIS, 2019, 13 : S395 - S396
  • [30] DEOXYTHIOGUANOSINE (DTG) IN DNA AS A PHARMACOLOGICAL ENDPOINT OF THIOPURINE TREATMENT IN INFLAMMATORY BOWEL DISEASE PATIENTS
    Coulthard, S.
    Berry, P.
    McGarrity, S.
    Kobayashi, T.
    Toyonaga, T.
    Ansari, A.
    Redfern, C.
    [J]. GUT, 2016, 65 : A261 - A261
12345